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Abstract
Adhesion of erythrocytes to endothelial cells lining the vascular wall can cause vaso-occlu-
sive events that impair blood flow which in turn may result in ischemia and tissue damage.
Adhesion of erythrocytes to vascular endothelial cells has been described in multiple hemo-
lytic disorders, especially in sickle cell disease, but the adhesion of normal erythrocytes to
endothelial cells has hardly been described. It was shown that calcium-loaded erythrocytes
can adhere to endothelial cells. Because sickle erythrocyte adhesion to ECs can be
enhanced by ultra-large von Willebrand factor multimers, we investigated whether calcium
loading of erythrocytes could promote binding to endothelial cells via ultra-large von Willeb-
rand factor multimers. We used (immunofluorescent) live-cell imaging of washed erythro-
cytes perfused over primary endothelial cells at venular flow rate. Using this approach, we
show that calcium-loaded erythrocytes strongly adhere to histamine-stimulated primary
human endothelial cells. This adhesion is mediated by ultra-large von Willebrand factor mul-
timers. Von Willebrand factor knockdown or ADAMTS13 cleavage abolished the binding of
erythrocytes to activated endothelial cells under flow. Platelet depletion did not interfere with
erythrocyte binding to von Willebrand factor. Our results reveal platelet-independent adhe-
sion of calcium-loaded erythrocytes to endothelium-derived von Willebrand factor. Erythro-
cyte adhesion to von Willebrand factor may be particularly relevant for venous thrombosis,
which is characterized by the formation of erythrocyte-rich thrombi.
Introduction
Healthy erythrocytes do not bind to the endothelial cells (ECs) that line the vascular wall. In
contrast, in multiple hematologic disorders [1–4] and most prominently in sickle (SS) cell dis-
ease, erythrocyte adhesion to ECs does occur [5]. This causes vaso-occlusive events that impair
blood flow which, in turn, can result in ischemia and tissue damage [5]. Since Hebbel et al.
observed the binding of SS erythrocytes to endothelial cells [6, 7], many mechanisms that may
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cause erythrocyte-EC adhesion have been described [5]. One of the most studied mechanisms
is the adhesion of SS erythrocytes to ECs via ultra-large VWF (ULVWF) multimers [8, 9]. In
vitro EC-derived ULVWF multimers can greatly enhance the adherence of SS erythrocytes to
ECs, but only slightly augment the adhesion of normal erythrocytes [8, 10]. An ex vivo rat
mesocecum perfusion model confirmed these results and showed that the release of VWF
from desmopressin-stimulated ECs significantly increased adhesion of SS erythrocytes to the
venular endothelium [9]. Also a correlation between the clinical severity of sickle cell disease,
deduced from the extent of hemolysis, and plasma levels of total active VWF was found [11].
Although the SS erythrocyte-EC interaction via ULVWF is well-accepted, the adhesion of
normal erythrocytes to ECs has hardly been described. In addition to SS erythrocytes, also cal-
cium-loaded erythrocytes can adhere to ECs [7]. Furthermore, in the ex vivo rat mesocecum
model perfused with desmopressin, it was shown that ULVWF released from ECs also pro-
moted the adhesion of normal erythrocytes to the venular endothelium [12]. Based on these
previous findings, we investigated whether calcium loading of erythrocytes could enhance the
binding of erythrocytes to ECs via ULVWF multimers. Our results reveal platelet-independent
adhesion of calcium-loaded erythrocytes to endothelium-derived VWF.
Methods
Erythrocytes and platelets isolation
Blood studies were approved by the Sanquin Research Institutional Medical Ethical Commit-
tee in accordance with the Dutch regulations and the 1964 Declaration of Helsinki standards.
Whole blood was collected in 3.8% sodium citrate tubes (Greiner Bio-One) from healthy,
anonymized volunteers that provided written informed consents which were approved by the
Sanquin Research Institutional Medical Ethical Committee. Platelet-rich plasma (PRP) was
separated from the erythrocyte-rich pellet by centrifugation at 200xg (15 minutes). The eryth-
rocytes were washed in SAGM (150 mM NaCl, 1.25 mM adenine, 28.82 mM mannitol, 49.95
mM D-glucose) and resuspended in SAGM (concentration ~ 3.5x109 cells/ml).
Acid citrate dextrose was added to the PRP (10% v/v) prior to centrifugation at 2000xg (5
minutes). The platelet pellet was washed twice with wash buffer (36 mM citric acid, 103 mM
NaCl, 5 mM KCl, 5 mM EDTA (ethylenediaminetetraacetic acid), 56 mM D-glucose, pH 6.5
containing 0.35% [wt/vol] bovine serum albumin) and resuspended to 200-400x106 cells/ml in
HEPES(+) buffer (132 mM NaCl, 20 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethane-
sulfonic acid), 6 mM KCl, 1 mM MgSO4•7H2O, 1.2 mM K2HPO4•3H2O, 2.5 mM CaCl2, 5.5
mM D-glucose, pH 7.4).
Cells were counted using an Advia 2120 Hematology System hematology analyzer
(Siemens).
Erythrocyte calcium loading or depletion
Erythrocytes (108 cells/ml) suspended in HEPES(+) (2.5 mM calcium) buffer, HEPES buffer
with the indicated concentrations of calcium, or HEPES buffer supplemented with 5 mM
EGTA (ethylene glycol tetraacetic acid) were treated with 1 μM ionomycin for 1 hour. Treated
erythrocytes were washed in HEPES(+) buffer with the equivalent calcium concentration,
stored at room temperature and resuspended, prior to a flow assay, in 1% BSA/HEPES(+) or
1% BSA/HEPES buffer without calcium supplemented with 5 mM EGTA. Both buffers were
supplemented with 100 μM histamine.
Erythrocytes and von Willebrand factor
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EC culture and flow chambers
Pooled human umbilical vein ECs (HUVECs) (Lonza), human aortic ECs (HAECs) (Lonza),
human microvascular ECs (HMEC-1) [13] (obtained from Dr Ades [Centers for Disease Con-
trol and prevention, Atlanta, GA]) and blood outgrowth ECs (BOECs) (isolated as described
previously [14]) were cultured in fibronectin (FN)-coated flasks in EBM-2 medium (Lonza)
supplemented with EGM-2 SingleQuot Kit Suppl. & Growth Factors (Lonza). ECs (7.5x104
cells/ml) were seeded in FN-coated μ-Slide VI 0.4 ibiTreat flow chambers (Ibidi). The ECs
were cultured for 5 days before flow experiments. When indicated, the ECs were stimulated
with 10 ng/ml TNF-α (Peprotech) for 24 hours. HUVECs were used until passage 5, BOECs
and HAECs until passage 7, and the cell line HMEC-1 until passage 15.
Live imaging of erythrocyte binding to ECs under flow
Erythrocytes (108 cells/ml) were incubated for one hour with 1 μM ionomycin or 10 μM vali-
nomycin. DMSO or H2O were used as controls. Erythrocytes (10
8 cells/ml) with or without
platelets (concentrations as indicated) or with or without monoclonal anti-VWF CLB-RAg20-
coupled [15] fluoresbrite YG microspheres (∅ 3 μm) (Polysciences) supplemented with
100 μM histamine, 1 U/ml thrombin, or vehicle were perfused for 10 minutes over ECs. All
perfusions were performed with a syringe pump (NE-1010 ProSense) at 0,57 ml/min which
gives a wall shear stress of 0.72 dyne/cm2 and a wall shear rate of 100 s-1. Real-time imaging
was performed by an Axiovert 200M microscope (Carl Zeiss Microscopy) with an Orca-R2
camera (Hamamatsu) using a 20x air objective.
Live fluorescent imaging under flow
Ionomycin- or control-treated erythrocytes (109 cells) were stained using PKH67GL (Sigma
Aldrich). Platelets (4x107 cells) were stained using anti-CD42b-APC (Life Technologies).
Alexa Fluor1568-labelled anti-VWF (Dako) antibody was prepared using a Zenon1 Alexa
Fluor1 568 Rabbit IgG Labeling Kit (Molecular Probes). Erythrocytes (108 cells/ml) with or
without platelets (4x106 cells/ml), anti-VWF Alexa Fluor1568 (1.2 μg/ml) and 100 μM hista-
mine were perfused over ECs for 10 minutes. Real-time imaging was performed using the
Axiovert 200M with a 40x oil objective (NA 1.3).
Effects of ADAMTS13 on erythrocyte binding to ECs under flow
Ionomycin-treated erythrocytes (108 cells/ml) were perfused with 100 μM histamine over ECs
for 10 minutes. Without flow interruption, perfusion was continued with or without 5% autol-
ogous platelet-poor-plasma or 5 μg/ml recombinant ADAMTS13 (purified as described before
[16]) for 10 minutes. At each time point images were acquired using an Axiovert 200M micro-
scope with a 20x air objective.
VWF knockdown
Six pre-tested VWF-specific shRNA constructs (Sigma MISSION1 TRC-Hs 2.0 shRNA
library) [17] were used in VWF knockdown and function interference experiments. The
results shown were obtained with TRCN0000373946 (ACATGGAAGTCAACGTTTATG, target-
ing nt 6360–6380 of VWF RefSeq NM_000552.3). The non-targeting hairpin control SHC002
(Sigma Aldrich) was used as a negative control. shRNA constructs were packaged into lenti-
viral particles in HEK293T cells after TransIT1LT1 (Mirus) mediated transfection together
with the pHDM-HgPM2, pRC-CMV-Rev1b, pHDMG-G, and pHDM-TAT1B packaging plas-
mids for 24 and 48 hours. HUVECs were transduced twice with a 24 hour interval. Forty eight
Erythrocytes and von Willebrand factor
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hours after the first transduction, 7.5x104 EC/ml were seeded in flow chambers and cultured
for 6 days, used for flow assays, fixed using paraformaldehyde (PFA) (4% w/v) for 15 minutes,
or lysed in sample buffer (0.125 M UltraPure Tris-HCl (tris(hydroxymethyl)aminomethane),
10% glycerol, 2% SDS, 2% β-mercapto-ethanol, 0.001% bromophenol blue, pH 6.8).
FACS analysis
Erythrocytes (108 cells/ml) in HEPES(+) buffer or HEPES buffer with 5 mM EGTA were
treated with 1 μM ionomycin or control (DMSO) for 1 hour. Erythrocytes (105 cells) were
incubated with BSA (1% w/v) for 15 minutes and subsequently stained using Annexin V-FITC
(BD Pharmingen) and anti-CD235a-PE (Sanquin) for 15 minutes. Phosphatidylserine (PS)
exposure was determined with a FACSCanto II flow cytometer (BD). Data were analyzed
using FlowJo version 10.0.8r1 (LLC).
Erythrocyte sorting
Erythrocyte ultra-purification was performed by fluorescence-activated cell sorting (FACS)
using a FACSAria III cell sorter (BD). Erythrocyte concentrates (107 cells/ml) were stained
using anti-CD235a-FITC (Sanquin) and anti-CD42b-APC (Life Technologies) for 30 minutes.
Erythrocytes were purified by positive sorting for CD235a and negative sorting for CD42b
with doublet exclusion by using FSC-H and FSC-W.
Western blot
Cell lysates were run on a 12.5% polyacrylamide gel and transferred onto Amersham™ Protan™
0.2 μm nitrocellulose blotting membranes (GE Healthcare). Membranes were stained using
anti-ICAM1 (Santa Cruz Biotechnology), anti-actin (Sigma Aldrich), anti-VWF (Dako)
overnight at 4˚C and counterstained with anti-mouse HRP (Dako) or anti-rabbit HRP (Dako)
for 1 hour. Immobilized antigens were detected by chemiluminescence using Pierce1ECL
Western Blotting Substrate (Thermo Scientific) and exposed on Fuji Medical X-Ray films
(Fujifilm).
Immunofluorescence imaging
Paraformaldehyde-fixed samples were permeabilized with Triton X-100 (0.5% v/v) for 5 min-
utes and blocked with BSA (2% w/v) for 30 minutes. ECs were stained with anti-VWF (Dako),
anti-VWF CLB-RAg20 (Sanquin), anti-VE-cadherin (Santa Cruz Biotechnology), or anti-
PECAM (Sanquin) for 1 hour. Next, ECs were stained with anti-Rabbit Alexa Fluor1488
(Thermo Fisher) and anti-Goat Alexa Fluor1633 (Thermo Fisher) for 1 hour. Fluorescent
images were acquired using a LSM510 Meta confocal microscope (Carl Zeiss) with a EC Plan-
Neofluar 40x oil objective (NA 1.3).
VWF ELISA
ECs were stimulated with HEPES(+) buffer containing 100 μM histamine for 10 minutes or
lysed in HEPES(+) buffer with Triton X-100 (1.0% v/v). Intracellular or secreted VWF was
assayed by sandwich enzyme-linked immunosorbent assay (ELISA) as described previously
[18] using rabbit polyclonal anti-VWF (DAKO) as coating antibodies and HRP-conjugated
rabbit polyclonal anti-VWF (DAKO) for detection of bound VWF. Standard curves were
made from dilutions of culture supernatants of HEK293 cells stably producing recombinant
VWF. Optical density levels measured below 2 times the blank were set to 0 pM.
Erythrocytes and von Willebrand factor
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Imaging and analysis
Images were taken using Zen 2012 software version 1.1.2.0 (Carl Zeiss). For all image process-
ing ImageJ version 1.49g (https://imagej.nih.gov/ij/) was used. Weibel-Palade bodies were
quantified using the functions “threshold” and “analyze particles” within regions of interest
based on the VE-cadherin staining. Erythrocyte adhesion was quantified using the ImageJ
plugin Cell Counter. Erythrocytes were qualified as firmly adherent when they remained
immobile for 5 seconds before and 5 seconds after each time point otherwise they were quali-
fied as loosely adherent. For each experiment, tile scans (3800 μm width) were made (S1 Fig).
Each data point represents the average number of adherent erythrocytes within 15 fields of
view (FOV; 1 FOV = 419.23x319.41 μm) (S1 Fig).
Statistical analysis
Data shown are mean ±SD. Statistical comparisons were made using an unpaired, 2-tailed Stu-
dent’s t test, 1-way ANOVA followed by Bonferroni’s post-hoc test, or 2-way ANOVA fol-
lowed by Bonferroni’s post-hoc test, where appropriate. Statistical analysis was performed
using GraphPad Prism version 6.04 (GraphPad Software). For all tests, results were considered
statistically significant at P< 0.05. Graphs showing individual data points are provided in S8
and S9 Figs.
Results
Erythrocyte binding to ECs
To analyze the adhesion of normal erythrocytes to primary human ECs, we used in vitro flow
chambers in which washed erythrocytes were perfused over cultured EC monolayers at a wall
shear rate of 100 s-1 and wall shear stress of 0,72 dyne/cm2 corresponding to the conditions in
post-capillary venules [19] or veins [20]. First we confirmed that the ECs formed a confluent
and stable monolayer within the perfusion chambers by staining for VE-cadherin. (Fig 1A).
We also confirmed that the ECs kept their endothelial phenotype after culturing in the perfu-
sion chambers by staining for VWF and VE-cadherin (S2 Fig) or PECAM (S2 Fig).
In contrast to SS erythrocytes, healthy erythrocytes do not bind to ECs [7], which we con-
firmed by perfusing freshly isolated normal erythrocytes over EC monolayers. An example of
this experiment can be seen in S1 Video. Previously, the release of ULVWF multimers from
ECs was shown to cause adhesion of normal erythrocytes to the venular endothelium in an ex
vivo rat mesocecum model [12]. Thrombin and histamine may induce increased release of
endothelial ULVWF multimers during episodes of vascular injury, inflammation, and infec-
tion [21, 22]. Yet, in our flow-model, washed erythrocytes that contained virtually no platelets
and white blood cells as shown in Table 1, showed little adhesion to ECs activated with 100 μM
histamine or 1 U/ml thrombin (Fig 1C and 1D).
However, since it has been described that calcium-loaded erythrocytes can adhere to ECs
[7], we tested the effect of calcium loading on erythrocyte-EC interaction. Erythrocyte treat-
ment with 1 μM ionomycin induced a rapid calcium influx followed by phosphatidylserine
exposure and cell volume decrease (S2 Fig). Interestingly, calcium-loaded erythrocytes
adhered to non-treated ECs (Fig 1C and 1D and S1 Video). Moreover, a double hit experimen-
tal set-up in which erythrocytes were loaded with calcium and perfused over histamine- or
thrombin-activated ECs, induced strong and abundant adhesion of erythrocytes to ECs (Fig
1C and 1D and S1 Video). In contrast, the pro-inflammatory cytokine TNF-α, which is also
secreted during injury, inflammation and infection, did not promote the binding of normal or
calcium-loaded erythrocytes to ECs, despite the upregulation of EC adhesion molecules such
Erythrocytes and von Willebrand factor
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Fig 1. Erythrocyte binding to ECs. (A) HUVECs cultured in perfusion chambers and stained for VE-Cadherin (red) and nuclei
(blue). The dashed box corresponds to the zoomed region. Scale bar represents 50 μm. (B) Erythrocytes treated for 1 hour with
ionomycin (1 μM) were perfused over histamine- (100 μM) activated HUVECs (37˚C and 5% CO2). Adhesion was recorded for
10 minutes. Images are stills from the video in S1 Video at the indicated times in minutes. The arrow indicates the direction of
the flow. The dashed box corresponds to the zoomed region. Scale bar represents 50 μm. (C) Quantification of adhesion of
ionomycin- (1 μM) or control-treated (1 hour) erythrocytes perfused (10 minutes) with or without histamine (100 μM) over
HUVECs. A schematic outline of the quantification method is shown in S1 Fig. (D) Ionomycin- or control-treated erythrocytes
perfused with or without thrombin (1 U/mL) over HUVECs. (E) Ionomycin- or control-treated erythrocytes perfused over TNF-α-
(10 ng/ml) or control-treated (24 hours) HUVECs. (F) Kinetics of ionomycin- or control-treated erythrocyte accumulation after
perfusion with or without histamine (100 μM) over HUVECs (Control-Control:●; Histamine-Control: ; Control-Ionomycin:■;
Histamine-Ionomcyin □). Adhesion of erythrocytes from 3 independent donors was quantified at a 1 minute time interval for 10
minutes. For C-E the average number of adherent erythrocytes within 15 fields of view (FOV; 1 FOV = 419.23x319.41 μm) was
used. For F the absolute number of adherent erythrocytes within 1 field of view was used. Values are means ± SD (n = 3; Each
n represents single independent experiments using cells from different donors). Statistical analysis was performed using a
2-way ANOVA in which all means were compared with the double-blank control followed by Bonferroni’s post-hoc test.
** P < 0.01; ****P < 0.0001.
doi:10.1371/journal.pone.0173077.g001
Erythrocytes and von Willebrand factor
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as intercellular adhesion molecule 1 (Fig 1E and S2 Fig). To test the effect of a different iono-
phore on erythrocyte adhesion to ECs we also stimulated erythrocytes with the potassium
ionophore valinomycin. Although valinomycin caused a significant potassium efflux from
erythrocytes, only minor adhesion of treated erythrocytes to ECs could be observed (S3 Fig).
To investigate the dynamics of the erythrocyte-endothelium adhesion process, ionomycin- or
control-treated erythrocytes from 3 independent donors were perfused with or without hista-
mine over ECs. Control treated erythrocytes showed both in the presence and absence of
histamine no adhesion to ECs (Fig 1F). On the contrary, the adhesion of calcium-loaded eryth-
rocytes in the absence of histamine increased during the first minutes after which an equilib-
rium between attaching and detaching cells established (Fig 1F). The double hit experimental
set-up induced strong and abundant adhesion of erythrocytes to ECs within the first minutes
followed by a gradual increase in absolute numbers of adherent cells (Fig 1F).
We also looked at the ratio between firmly adherent erythrocytes and loosely adherent
erythrocytes (S4 Fig). Although some erythrocytes detach after adhering to ECs (S1 Video),
quantification showed that both in the ionomycin-treated condition as in the double hit exper-
imental set-up the absolute number of loosely adherent erythrocytes is small (S4 Fig). The
maximal amount of loosely adherent erythrocytes was observed after 10 minutes perfusion of
ionomycin-treated erythrocytes over histamine-treated ECs. Here, the amount of loosely
adherent erythrocytes peaked at 8% (S4 Fig).
These data show that adhesion of erythrocytes to ECs can be induced by calcium accumula-
tion within the erythrocytes and is greatly enhanced upon the activation of ECs by either hista-
mine or thrombin.
Intracellular calcium accumulation potentiates erythrocyte adhesion to
ECs
Before we tested whether ULVWF multimers were involved in the adhesion of calcium-loaded
erythrocytes to ECs, we determined the role of calcium in this process. While intracellular cal-
cium is important for cell signaling [23], extracellular calcium is important for maintaining a
functional conformation of adhesion molecules [24]. Preventing the ionomycin-induced intra-
cellular increase of calcium (Fig 2Ai) by 5 mM EGTA pre-incubation (Fig 2Aii) caused an
almost complete (~92%) reduction of erythrocyte adhesion to histamine-activated ECs (Fig
2B). When extracellular calcium was removed by adding 5 mM EGTA to the flow buffer after
the ionomycin-induced calcium influx (Fig 2Aiii), only a 32% reduction in erythrocyte-EC
adhesion was observed (Fig 2B). Significantly less erythrocytes adhered to ECs when intracel-
lular calcium was kept low compared with a reduction in extracellular calcium (Fig 2B). When
erythrocyte calcium influx was induced in the presence of varying calcium concentrations,
increasing erythrocyte-EC adhesion could be observed at a calcium concentration of 25 μM
and higher (Fig 2C). A significant increase of erythrocyte-EC adhesion was observed at intra-
cellular calcium levels of 50 μM and higher. (Fig 2C). These results suggest that the adhesion of
Table 1. Blood cell counts measured from the washed erythrocyte concentrates used in Fig 1C and
1D.
Mean absolute number (x109 cells / L) and range
(x109 cells / L)
Percentage of total and
range (%)
Erythrocytes 3267 (2450–3700) 99.88 (99.75–99.97)
Platelets 2.67 (0–6) 0.10 (0.00–0.24)
White blood
cells
0.82 (0.16–1.34) 0.02 (0.007–0.036)
doi:10.1371/journal.pone.0173077.t001
Erythrocytes and von Willebrand factor
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erythrocytes to activated ECs depends on intracellular calcium accumulation whereas extracel-
lular calcium is not required for erythrocyte-EC binding.
Von Willebrand factor mediates erythrocyte-EC binding
Next we determined whether ULVWF multimers from the ECs were involved in the adhesion
of calcium-loaded erythrocytes to ECs. Interestingly, calcium-loaded erythrocytes bound at
low levels in a random fashion to control-treated ECs (Fig 3A and 3B left panels), while cal-
cium-loaded erythrocytes perfused over histamine- or thrombin-activated ECs adhered in
high numbers and clusters of adherent cells aligned in the direction of the flow (Fig 3A and 3B
right panels). The alignment of erythrocytes adherent to ECs resembled platelet-binding to
VWF (Fig 3C and 3D). We therefore investigated the role of VWF in erythrocyte-EC interac-
tion by perfusing monoclonal anti-VWF coupled beads (CLB-RAg20-beads) together with
calcium-loaded erythrocytes over histamine-activated ECs to visualize the VWF strings. The
CLB-RAg20-beads bound, together with the erythrocytes, to the ECs and aligned along the
same track as the erythrocytes in the direction of the flow (Fig 3E and S5 Fig).
We also perfused PKH67-labeled calcium-loaded erythrocytes in combination with Alexa
Fluor1568-conjugated polyclonal anti-VWF antibodies over histamine-activated ECs which
confirmed that erythrocytes adhered to EC-derived VWF strings (Fig 4A; S2 Video).
The plasma metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13) can cleave VWF strings [25]. The binding of cal-
cium-loaded erythrocytes to histamine-activated ECs did not change after subsequent perfu-
sion of control HEPES buffer (Fig 4Bi), but was significantly reduced after perfusion of 5%
Fig 2. Intracellular calcium accumulation potentiates erythrocyte adhesion to ECs. (A) Schematic
representation of the different experimental conditions used to analyze the role of intra- and extracellular calcium for
erythrocyte adhesion to ECs. (i) Ionomycin- (1 μM) treated (1 hour) erythrocytes perfused (10 minutes) using a
calcium-rich buffer. (ii) Ionomycin plus EGTA- (5 mM) treated erythrocytes perfused using a calcium-rich buffer. (iii)
Ionomycin-treated erythrocytes perfused using an EGTA-supplemented buffer. (I = Ionomycin, E = EGTA) (B)
Quantification of adhesion of erythrocytes treated as described in panel A perfused (10 minutes) with histamine
(100 μM) over HUVECs. (C) Quantification of adhesion of erythrocytes loaded with increasing concentrations of
calcium perfused (10 minutes) with histamine (100 μM) over HUVECs. Adherent erythrocytes were quantified as in Fig
1. Values are means ± SD (n = 4; Each n represents single independent experiments using cells from different
donors). Statistical analysis was performed using a 1-way ANOVA (B) or a 1-way ANOVA in which all means were
compared with 0 μM calcium (C) each followed by Bonferroni’s post-hoc test. * P < 0.05; ** P < 0.01; ***P < 0.001;
****P < 0.0001.
doi:10.1371/journal.pone.0173077.g002
Erythrocytes and von Willebrand factor
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autologous plasma or 5 μg/ml recombinant ADAMTS13 over the adherent erythrocytes (Fig
4Bii and 4Biii respectively). This indicates that VWF cleavage prevents erythrocyte adhesion to
activated ECs.
Finally, lentivirally transduced short hairpin RNA against VWF significantly reduced the
endothelial VWF levels (Fig 4C), caused a loss of VWF-positive endothelial Weibel-Palade
bodies (S6 Fig) and reduced VWF string formation upon histamine activation of ECs (S6 Fig).
Importantly, VWF knockdown significantly reduced the adhesion of calcium-loaded erythro-
cytes to histamine-activated ECs (Fig 4C). Together, these results suggest that the adhesion of
calcium-loaded erythrocytes to histamine-activated ECs depends on ULVWF strings.
VWF levels determine binding of calcium-loaded erythrocytes to ECs
In addition to HUVECs, we investigated erythrocyte adhesion to blood outgrowth ECs
(BOECs), which are more closely related to microvascular endothelial cells [26], human aortic
ECs (HAECs), and a human microvascular EC line (HMEC-1). As we observed with HUVECs
(Fig 5A), the double hit experimental design induced the most abundant erythrocyte-EC adhe-
sion to BOECs (Fig 5B), HAECs (Fig 5C), and HMEC-1 (Fig 5D), albeit that the absolute num-
ber of adherent erythrocytes differed between EC types with lowest binding to the HMEC-1
cell line. Next, we questioned whether differences between intracellular VWF levels of the vari-
ous EC types could explain the different amounts of adherent erythrocytes. VWF stainings of
the different EC types showed a reduction of Weibel-Palade bodies in the HAECs compared to
the HUVECs and the BOECs and an almost complete absence in the HMEC-1 cell line (Fig 5E
and S7 Fig). This suggests reduced VWF levels in the HAECs and the HMEC-1 cell line. This
was confirmed when we measured both intracellular VWF levels and histamine-induced,
Fig 3. Erythrocytes adherent to activated ECs align in the flow direction. (A) Ionomycin- (1 μM) treated (1 hour)
erythrocytes perfused (10 minutes) without (left panel) or with histamine (100 μM) (right panel) over HUVECs. (B) Ionomycin-
treated (1 hour) erythrocytes perfused without (left panel) or with (right panel) thrombin (1 U/ml) over HUVECs. The dashed
boxes correspond to the zoomed regions. The arrow indicates the direction of the flow. (C) Ionomycin-treated erythrocytes
perfused with histamine over HUVECs. Adherent erythrocytes are marked by (*). (D) Platelets perfused (10 minutes) with
histamine (100 μM) over HUVECs. Adherent platelets are marked by arrowheads. (E) Ionomycin-treated erythrocytes mixed
with monoclonal anti-VWF CLB-RAg20-coupled fluoresbrite YG microspheres (∅ 3 μm) perfused (10 minutes) with histamine
over HUVECs. Scale bars represent 50 μm.
doi:10.1371/journal.pone.0173077.g003
Erythrocytes and von Willebrand factor
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secreted VWF levels (Fig 5F and 5G). By plotting the absolute number of ionomycin treated
erythrocytes adherent to histamine treated ECs against secreted VWF levels a positive correla-
tion between VWF levels and erythrocyte adhesion could be observed (Fig 5H). These data
show that erythrocyte-EC adhesion is not specific to HUVECs and can be observed using ECs
from different vascular beds, however the extent of erythrocyte adhesion depends on the VWF
levels of the ECs.
Erythrocytes bind independent of platelets to VWF
Platelets are the main cells that bind VWF [27]. We questioned whether erythrocytes bind to
VWF strings in a fashion independent of platelet binding. Calcium-loaded erythrocytes,
mixed with platelets, and perfused over histamine-activated ECs, bound side-by-side to the
same VWF strings (Fig 6A and 6B). Furthermore, in the presence of increasing numbers of
platelets, there was no significant increase in the number of adherent erythrocytes (Fig 6B).
The platelet integrin αIIBβ3 has been described to bind to the erythrocyte membrane mole-
cule ICAM-4 [28] thereby facilitating erythrocyte binding to VWF [29]. However, we observed
platelet-independent binding of erythrocytes to VWF from histamine-activated ECs using live
immunofluorescent imaging of anti-CD235a-FITC-labeled calcium-loaded erythrocytes
mixed with CD42b-APC-labeled platelets and Alexa Fluor1568-labeled anti-VWF antibodies
Fig 4. VWF mediates erythrocyte adhesion to ECs. (A) Ionomycin- (1 μM) treated (1 hour) erythrocytes labeled with
PKH67 (green), mixed with Alexa Fluor®568-labelled anti-VWF antibody (red) perfused (10 minutes) with histamine (100 μM)
over HUVECs. The dashed box corresponds to the zoomed region. Scale bar represents 50 μm. (B) Quantification of
adhesion of ionomycin-treated erythrocytes perfused (10 minutes) with histamine over HUVECs (Ctrl), followed by 10 minutes
perfusion with (i) control buffer (Buffer), (ii) 5% autologous plasma (Plasma), or (iii) 5 μg/ml ADAMTS13 (ADAMTS13). (C)
Quantification of adhesion of ionomycin-treated erythrocytes perfused with histamine over HUVECs transduced with lentivirus
encoding a control short hairpin (shCtrl) or a short hairpin against VWF (shVWF). Adherent erythrocytes were quantified as in
Fig 1. (D) Western blot and densitometric quantification of VWF levels in cell lysates of the lentivirally transduced HUVECs.
Values are means ± SD (n = 3; Each n represents single independent experiments using cells from different donors).
Statistical analysis was performed using a 2-tailed Student’s t test. * P < 0.05; ** P < 0.01.
doi:10.1371/journal.pone.0173077.g004
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(Fig 6B). Furthermore, erythrocytes purified by FACS, based on the expression of CD235a and
lack of CD42b, bound to EC-derived VWF strings (Fig 6C). Together, these results suggest
that calcium-loaded erythrocytes can bind, independent of platelets, to VWF strings and that
platelets and erythrocytes do not show significant competition for binding sites on ULVWF
strings.
Discussion
Under physiological flow, erythrocytes do not adhere to the vessel wall. In contrast to erythro-
cytes, platelets do adhere to the vessel wall under flow, provided the endothelium is activated.
Such activation, for example by histamine [22] or thrombin [21], induces the release of VWF
from Weibel-Palade bodies. Platelets will adhere to unfolded VWF under flow and thereby
participate in primary hemostasis (Fig 7A) [30]. The current study shows that calcium-loaded
erythrocytes can also adhere, in a platelet-independent fashion, to VWF strings released by
activated ECs (Fig 7B).
Accumulation of calcium within erythrocytes is associated with a number of hereditary ane-
mias including sickle cell disease [23, 31], however calcium influxes into normal erythrocytes
Fig 5. VWF levels determine binding of calcium-loaded erythrocytes to ECs. (A) Quantification of adhesion of ionomycin-
(1 μM) or control-treated (1 hour) erythrocytes perfused (10 minutes) with or without histamine (100 μM) over HUVECs, (B)
BOECs, (C) HAECs, or (D) the cell line HMEC-1. Adherent erythrocytes were quantified as in Fig 1. (E) Quantification of VWF-
positive area per cell based on VE-Cadherin and VWF stained HUVECs, BOECs, HAECs, and the cell line HMEC-1. (F)
Intracellular VWF levels and (G) secreted VWF levels after 10 minutes induction by histamine (100 μM) from HUVECs, BOECs,
HAECs, and the cell line HMEC-1 measured by ELISA. (H) The absolute number of ionomycin-treated erythrocytes adherent to
histamine-treated ECs (obtained from A-D) are plotted against secreted VWF levels (pmol) (obtained from G). Different EC types
are marked:●HUVEC;▲ BOEC;■HAEC;▼HMEC1. Values are means ± SD (n = 3; Each n represents single independent
experiments using cells from different donors). Statistical analysis was performed using a 2-way ANOVA in which all means
were compared with the double-blank control (A-D) or a 1-way ANOVA in which all means were compared with HUVECs (E-G)
each followed by Bonferroni’s post-hoc test. * P < 0.05; ** P < 0.01; ***P < 0.001; ****P < 0.0001.
doi:10.1371/journal.pone.0173077.g005
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Fig 6. Erythrocytes bind VWF through a platelet-independent mechanism. (A) Ionomycin- (1 μM) treated (1 hour)
erythrocytes, mixed with platelets and perfused (10 minutes) with histamine (100 μM) over HUVECs. An example of an
adherent platelet is marked by (*) and an adherent erythrocyte is marked by an arrowhead. (B) Ionomycin-treated
erythrocytes labeled with anti-CD235a-FITC (green), mixed with anti-CD42b-APC-labeled platelets (magenta) and Alexa
Fluor®568-labelled anti-VWF antibody (red) were perfused with histamine over HUVECs. Adherent erythrocytes were
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have also been described. For instance, calcium influxes were observed after erythrocyte cold
storage [32]. Furthermore, the expression of a NMDA receptor channel on erythrocyte mem-
branes has been reported for rat [33] and later in human erythrocytes [34]. It was shown that
NMDA receptor agonists including glutamate, N-methyl D-aspartate (NMDA), homocysteic
acid, and glycine could raise erythrocyte intracellular calcium levels [34]. Furthermore, lyso-
phosphatidic acid (LPA), a second messenger generated by activated platelets that assists in
clot formation, was shown to cause a calcium influx into erythrocytes [35, 36]. Whether these
stimuli would cause a sufficient raise in intracellular calcium to induce the binding of erythro-
cytes to VWF remains to be established.
quantified as in Fig 1. Values are means ± SD (n = 3; Each n represents single independent experiments using cells from
different donors). Statistical analysis was performed using a 1-way ANOVA in which all means were compared with 0
platelets ml-1 followed by Bonferroni’s post-hoc test. (C) Erythrocytes were purified by FACS. The erythrocyte population
based on cell size (i) was positive sorted for CD235a-FITC and negative sorted for CD42b-APC (ii). Purified erythrocytes
(107 cells/ml) treated (1 hour) with ionomycin (1 μM) (green), mixed with Alexa Fluor®568-labelled anti-VWF antibody (red)
were perfused with histamine (100 μM) over HUVECs. (iii) The dashed box corresponds to the zoomed region. Scale bars
represent 50 μm.
doi:10.1371/journal.pone.0173077.g006
Fig 7. A double hit model describes erythrocyte adhesion to vascular ECs. (A) A single hit model for the
adhesion of circulating cells to activated endothelium is shown. Endothelial activation by histamine [22] or thrombin
[21] leads to the release of VWF from Weibel-Palade bodies. Platelets adhere to VWF under flow and thereby
contribute to primary hemostasis [27]. Normal erythrocytes do not adhere to VWF and remain in circulation. (B)
Double hit model for adhesion of circulating cells to ECs. ECs, activated by histamine or thrombin, release VWF
from Weibel-Palade bodies. Platelets adhere to the VWF strings. In addition, calcium-loaded erythrocytes can
adhere independently of platelets to VWF strings. Micro-thrombi-like structures are formed.
doi:10.1371/journal.pone.0173077.g007
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Besides the erythrocyte binding to ULVWF strings which we describe here, erythrocyte
adhesion to endothelial cells can also be mediated by many other mechanisms. The endo-
thelial proteins αVβ3 [37], and P-selectin [38] and the erythrocyte proteins BCAM/Lu [2],
CD44 [37], and CD36 [39, 40] were also shown to facilitate an EC-erythrocyte interaction.
However, if any of these receptors were involved in the adhesion of calcium-loaded erythro-
cytes to ECs, this interaction should also occur in the absence of ULVWF multimers.
Although our results do not rule out a possible partial contribution of adhesion mecha-
nisms, other than through VWF, the ADAMTS13 cleavage- and the VWF-knockdown
experiments showed that the majority of calcium-loaded erythrocytes adhere to endothelial
cells via ULVWF strings.
The reduced adhesion of calcium-loaded erythrocytes to ECs from microvascular beds
(HMEC-1) compared to ECs from macrovascular beds (HUVEC, and HAEC) seems contra-
dictory to previous studies. Microcirculatory studies using ex vivo mesocecum vasculature of
the rat showed a strong inverse correlation between adhesion of SS erythrocytes and the venu-
lar diameter [9, 19]. However, in our experiments we applied a similar wall shear stress on the
different EC types, while in the ex vivo model, the wall shear stress changes along the vascula-
ture which thereby could interfere with erythrocyte adhesion. Furthermore, we showed a posi-
tive correlation between the amount of ULVWF produced by the different types of endothelial
cells with the amount of adherent, calcium-loaded erythrocytes. Although the microvascular
endothelial cell line HMEC-1 produced barely any VWF, the VWF levels of the primary
HUVEC, BOEC, and HAECs were in line with previous results [41]. These differences could
explain the apparent contradiction.
Platelets are the main cells to bind to VWF. Erythrocyte ICAM-4 can bind the platelet
integrin αIIBβ3 [28]. Thus, platelets could potentially facilitate the erythrocyte-VWF interaction
[29]. In this study we show that an ultra-pure erythrocyte population can in vitro adhere to
VWF in a platelet-independent fashion. This does not exclude that platelet-erythrocyte com-
plexes could enhance erythrocyte-VWF binding, but our data suggests that the contribution of
platelets to erythrocyte binding is limited.
The function of erythrocyte binding to VWF is not known. However, increasing evidence
shows that erythrocytes play an important role in hemostasis [29]. Their rheological proper-
ties cause platelets to be concentrated in the periphery of the blood vessels, close to the
vessel wall [42]. In addition, the negative surface of PS-exposing erythrocytes facilitates
thrombin generation [43]. Erythrocytes also play an important role in thrombosis. In con-
trast to white arterial thrombi that consist mainly of platelets, erythrocytes are the major
cellular component of red venous thrombi [44, 45]. Our in vitro results show that VWF-
associated erythrocytes will readily form thrombus-like structures. In vivo, VWF-/- mice
were shown to be protected from thrombosis in a deep venous thrombosis model by pre-
venting the adhesion of platelets and leukocytes to the vascular endothelium [46]. A similar
erythrocyte-VWF interaction may therefore contribute to the formation or propagation of
venous thrombi.
In summary, this study shows that erythrocyte adhesion to ECs is rapidly induced when (i)
erythrocytes undergo a calcium-influx and (ii) VWF is released from ECs. Our work shows
that the adhesion of erythrocytes to ECs is mediated by newly released ULVWF strings and is
independent of platelets. The calcium-loaded erythrocytes interact with endothelial-bound
ULVWF strings through unidentified receptors. Future work is needed to define the molecular
characteristics of erythrocyte receptors that can bind VWF as well as the VWF domain that is
responsible for this interaction. Finally, investigating whether the erythrocyte-VWF interac-
tions could play a role in hemostasis and (venous) thrombosis and exploring ways to modulate
these interactions will likely prove to be of clinical relevance.
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Supporting information
S1 Fig. Example of the standardized method used for quantification of adherent erythro-
cytes. (A) An example of the raw data acquired which was used for quantification of adhe-
sion of ionomycin-treated erythrocytes perfused with histamine over HUVECs. For each
experiment the average number of adherent erythrocytes within 15 fields of view (FOV; 1
FOV = 419.23x319.41 μm) represented by the colored numbers was used. The arrow indi-
cates the direction of flow. The dashed box corresponds to the zoomed region. Scale bar
represents 500 μm. (B) Magnification of a single FOV showing the counted adherent eryth-
rocytes marked by turquoise colored numbers (2). Scale bar represents 50 μm. (C) Raw data
representing the quantification of adherent erythrocytes from one single condition from one
single donor.
(TIF)
S2 Fig. Additional controls for erythrocyte and endothelial activation. (A) HUVECs were
cultured in perfusion chambers and were stained for VWF (green) and VE-Cadherin (red) or
(B) PECAM (red) and nuclei (blue). The dashed boxes correspond to the zoomed regions.
Scale bars represent 50 μm. (C-D) Erythrocytes were treated (1 hour) with Ionomycin (1 μM)
or DMSO in the presence or absence of EGTA (5 mM). Phosphatidylserine exposure (C) and
relative size (D) of Annexin V-FITC and anti-CD235a-PE labeled erythrocytes (105 cells) were
determined with a FACSCanto II flow cytometer (BD). (E) Western blot and densitometric
quantification of ICAM-1 levels in cell lysates of control- or TNF-α-(10 ng/ml) treated (24
hour) HUVECs. Values are means ± SD (n = 3; Each n represents single independent experi-
ments using cells from different donors). Statistical analysis was performed using a 1-way
ANOVA followed by Bonferroni’s post-hoc test (C) or a 2-tailed Student’s t test (D-E).
 P< 0.05;  P< 0.01;  P< 0.001.
(TIF)
S3 Fig. Valinomycin and erythrocyte-EC adhesion. (A) Valinomycin- (10 μM) or control-
treated (1 hour) erythrocytes perfused (10 minutes) with or without histamine (100 μM) over
HUVECs. Adherent erythrocytes were quantified as in Fig 1. Values are means ± SD (n = 3;
Each n represents single independent experiments using cells from different donors). Statisti-
cal analysis was performed using a 2-way ANOVA in which all means were compared with the
double-blanc control followed by Bonferroni’s post-hoc test. (B) Extracellular potassium levels
of valinomycin- or control-treated erythrocytes measured by a blood gas analyzer. Values are
means ± SD (n = 3; Each n represents single independent experiments using cells from differ-
ent donors). Statistical analysis was performed using a 1-way ANOVA in which all means were
compared with the DMSO control.  P< 0.01;  P< 0.001.
(TIF)
S4 Fig. Firmly adherent erythrocytes versus loosely adherent erythrocytes. (A) Absolute
number of firmly and loosely adherent erythrocytes after perfusion (2.5, 5, or 10 minutes) of
ionomycin- (1 μM) treated (1 hour) erythrocytes with or without histamine (100 μM) over
HUVECs. (B) Percentages of firmly and loosely adherent erythrocytes. Erythrocytes were qual-
ified as firmly adherent when they remained immobile for 5 seconds before and 5 seconds
after each time point, otherwise they were qualified as loosely adherent. Adherent erythrocytes
were quantified as in Fig 1. All bars represent the average of three independent experiments.
(n = 3; Each n represents single independent experiments using cells from different donors)
The open bars represent firmly adherent erythrocytes. The filled bars represent loosely adher-
ent erythrocytes.
(TIF)
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S5 Fig. Erythrocytes and CLB-RAg20-beads adhere to ECs. Ionomycin- (1 μM) treated (1
hour) erythrocytes mixed with monoclonal anti-VWF CLB-RAg20-coupled fluoresbrite YG
microspheres (∅ 3 μm) (green) perfused (10 minutes) with histamine (100 μM) over
HUVECs. The dashed box corresponds to the zoomed region. Scale bars represent 50 μm.
(TIF)
S6 Fig. VWF knockdown in ECs. (A) HUVECs lentivirally transduced with a control short
hairpin (shCtrl) or a short hairpin against VWF (shVWF) were fixed using 4% PFA and
stained for VWF (green) and VE-Cadherin (red). (B) Alexa Fluor1568-labelled anti-VWF
antibody (red) perfused (10 minutes) with histamine (100 μM) over lentivirally transduced
HUVECs expressing a control short hairpin (shCtrl) or a short hairpin against VWF
(shVWF). The dashed box corresponds to the zoomed region. Scale bars represent 50 μm.
(TIF)
S7 Fig. Weibel-Palade bodies in different types of ECs. HUVECs, BOECs, HAECs, and the
cell line HMEC-1 were fixed using 4% PFA and stained for VWF (green) and VE-Cadherin
(red). The dashed box corresponds to the zoomed region. Scale bars represent 50 μm.
(TIF)
S8 Fig. Individual data points from Figs 1–4. The individual data points from respectively
(A) Fig 1, (B) Fig 2, and (C) Fig 4 are shown.
(TIF)
S9 Fig. Individual data points from Fig 5 –S4 Fig. The individual data points from respec-
tively (A) Fig 5, (B) Fig 6, (C) S2 Fig, (D) S3 Fig, and (E) S4 Fig are shown.
(TIF)
S10 Fig. Original western blot data. (A) The original full scale film of the ICAM-1 control
from S2 Fig. (B) The original full scale film of the VWF knockdown check from Fig 4. The first
layer of a stacked exposure is shown. (C) The third film layer of the stacked exposure of the
VWF knockdown check from Fig 4 is shown.
(TIF)
S1 Video. Erythrocyte adhesion to endothelial cells under flow. Ionomycin- (1 μM) or con-
trol-treated (1 hour) erythrocytes perfused (10 minutes) with or without histamine (100 μM)
over HUVECs.
(AVI)
S2 Video. Fluorescently labeled erythrocytes adhere to immunofluorescently labeled VWF
under flow.
(AVI)
Acknowledgments
The authors thank Paul Kaijen and Fabian Verbij for rADAMTS13 purification and Mark
Hoogenboezem for erythrocyte purification by FACS.
Author Contributions
Conceptualization: MWJS PLH.
Data curation: MWJS RB HM FPJM.
Formal analysis: MWJS RB HM FPJM.
Erythrocytes and von Willebrand factor
PLOS ONE | DOI:10.1371/journal.pone.0173077 March 1, 2017 16 / 19
Investigation: MWJS RB HM FPJM.
Methodology: MWJS.
Resources: DG.
Supervision: PLH.
Visualization: MWJS.
Writing – original draft: MWJS.
Writing – review & editing: MWJS RB HM FPJM JMD APJV JV PLH.
References
1. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic
erythrocytes to endothelial cells. Br J Haematol. 1999; 106(1):178–81. Epub 1999/08/12. PMID:
10444184
2. Wautier MP, El Nemer W, Gane P, Rain JD, Cartron JP, Colin Y, et al. Increased adhesion to endothe-
lial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and
Lu/BCAM. Blood. 2007; 110(3):894–901. Epub 2007/04/07. doi: 10.1182/blood-2006-10-048298 PMID:
17412890
3. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, et al. Altered erythrocyte endo-
thelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood. 2003; 101
(11):4625–7. Epub 2003/02/01. doi: 10.1182/blood-2001-12-0329 PMID: 12560240
4. Smith BD, Segel GB. Abnormal erythrocyte endothelial adherence in hereditary stomatocytosis. Blood.
1997; 89(9):3451–6. Epub 1997/05/01. PMID: 9129053
5. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004; 364(9442):1343–60. Epub 2004/10/12. doi: 10.
1016/S0140-6736(04)17192-4 PMID: 15474138
6. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-
cell anemia. A possible determinant of disease severity. N Engl J Med. 1980; 302(18):992–5. Epub
1980/05/01. doi: 10.1056/NEJM198005013021803 PMID: 7366623
7. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle
erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in
sickle cell disease. J Clin Invest. 1980; 65(1):154–60. Epub 1980/01/01. doi: 10.1172/JCI109646 PMID:
7350195
8. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, McIntire LV. Unusually large von Willebrand fac-
tor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow.
J Clin Invest. 1987; 80(3):905–10. Epub 1987/09/01. doi: 10.1172/JCI113151 PMID: 3497953
9. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation:
the role of von Willebrand factor and implications for vasoocclusion. Blood. 1993; 81(9):2429–38. Epub
1993/05/01. PMID: 8481522
10. Wick TM, Moake JL, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferen-
tially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hematol.
1993; 42(3):284–92. Epub 1993/03/01. PMID: 8438902
11. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, Lopez JA. The rate of hemolysis in sickle cell dis-
ease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011; 117
(13):3680–3. Epub 2011/02/09. doi: 10.1182/blood-2010-08-302539 PMID: 21300978
12. Tsai HM, Sussman II, Nagel RL, Kaul DK. Desmopressin induces adhesion of normal human erythro-
cytes to the endothelial surface of a perfused microvascular preparation. Blood. 1990; 75(1):261–5.
Epub 1990/01/01. PMID: 2294989
13. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. HMEC-1: establishment
of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992; 99(6):683–90.
PMID: 1361507
14. Martin-Ramirez J, Hofman M, van den Biggelaar M, Hebbel RP, Voorberg J. Establishment of out-
growth endothelial cells from peripheral blood. Nat Protoc. 2012; 7(9):1709–15. doi: 10.1038/nprot.
2012.093 PMID: 22918388
15. Stel HV, Sakariassen KS, Scholte BJ, Veerman EC, van der Kwast TH, de Groot PG, et al. Characteri-
zation of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-
Erythrocytes and von Willebrand factor
PLOS ONE | DOI:10.1371/journal.pone.0173077 March 1, 2017 17 / 19
induced platelet aggregation and platelet adherence to subendothelium. Blood. 1984; 63(6):1408–15.
PMID: 6426553
16. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising
residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2
domain of VWF. Blood. 2010; 115(8):1640–9. doi: 10.1182/blood-2009-06-229203 PMID: 20032502
17. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening
with a lentiviral RNAi library. Nat Methods. 2006; 3(9):715–9. doi: 10.1038/nmeth924 PMID: 16929317
18. Knipe L, Meli A, Hewlett L, Bierings R, Dempster J, Skehel P, et al. A revised model for the secretion of
tPA and cytokines from cultured endothelial cells. Blood. 2010; 116(12):2183–91. doi: 10.1182/blood-
2010-03-276170 PMID: 20538801
19. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascu-
lar endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A.
1989; 86(9):3356–60. PMID: 2497465
20. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996; 88
(5):1525–41. PMID: 8781407
21. Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB. Thrombin-mediated release of factor VIII
antigen from human umbilical vein endothelial cells in culture. Blood. 1982; 60(2):531–4. PMID:
6807373
22. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in
human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluores-
cent probe indo-1. J Clin Invest. 1987; 79(2):600–8. doi: 10.1172/JCI112853 PMID: 3492515
23. Bogdanova A, Makhro A, Wang J, Lipp P, Kaestner L. Calcium in red blood cells-a perilous balance. Int
J Mol Sci. 2013; 14(5):9848–72. doi: 10.3390/ijms14059848 PMID: 23698771
24. Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell
Biol. 2011; 12(3):189–97. doi: 10.1038/nrm3068 PMID: 21346732
25. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of
the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413(6855):488–
94. doi: 10.1038/35097008 PMID: 11586351
26. Jiang A, Pan W, Milbauer LC, Shyr Y, Hebbel RP. A practical question based on cross-platform microar-
ray data normalization: are BOEC more like large vessel or microvascular endothelial cells or neither of
them? J Bioinform Comput Biol. 2007; 5(4):875–93. PMID: 17787061
27. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle.
Blood. 2013; 121(2):270–7. doi: 10.1182/blood-2012-07-442285 PMID: 23093621
28. Hermand P, Gane P, Huet M, Jallu V, Kaplan C, Sonneborn HH, et al. Red cell ICAM-4 is a novel ligand
for platelet-activated alpha IIbbeta 3 integrin. J Biol Chem. 2003; 278(7):4892–8. doi: 10.1074/jbc.
M211282200 PMID: 12477717
29. Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythro-
cytes in thrombus formation. Semin Thromb Hemost. 2014; 40(1):72–80. doi: 10.1055/s-0033-1363470
PMID: 24356930
30. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, et al. Platelets adhere to and trans-
locate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000; 96
(10):3322–8. PMID: 11071623
31. Bookchin RM, Lew VL. Progressive inhibition of the Ca pump and Ca:Ca exchange in sickle red cells.
Nature. 1980; 284(5756):561–3. PMID: 6445042
32. Wiley JS, McCulloch KE, Bowden DS. Increased calcium permeability of cold-stored erythrocytes.
Blood. 1982; 60(1):92–8. PMID: 7082850
33. Makhro A, Wang J, Vogel J, Boldyrev AA, Gassmann M, Kaestner L, et al. Functional NMDA receptors
in rat erythrocytes. Am J Physiol Cell Physiol. 2010; 298(6):C1315–25. doi: 10.1152/ajpcell.00407.2009
PMID: 20457837
34. Makhro A, Hanggi P, Goede JS, Wang J, Bruggemann A, Gassmann M, et al. N-methyl-D-aspartate
receptors in human erythroid precursor cells and in circulating red blood cells contribute to the intracellu-
lar calcium regulation. Am J Physiol Cell Physiol. 2013; 305(11):C1123–38. doi: 10.1152/ajpcell.00031.
2013 PMID: 24048732
35. Yang L, Andrews DA, Low PS. Lysophosphatidic acid opens a Ca(++) channel in human erythrocytes.
Blood. 2000; 95(7):2420–5. PMID: 10733516
36. Kaestner L, Steffen P, Nguyen DB, Wang J, Wagner-Britz L, Jung A, et al. Lysophosphatidic acid
induced red blood cell aggregation in vitro. Bioelectrochemistry. 2012; 87:89–95. doi: 10.1016/j.
bioelechem.2011.08.004 PMID: 21890432
Erythrocytes and von Willebrand factor
PLOS ONE | DOI:10.1371/journal.pone.0173077 March 1, 2017 18 / 19
37. Chiou E, Zennadi R. Galphas proteins activate p72(Syk) and p60-c-Src tyrosine kinases to mediate
sickle red blood cell adhesion to endothelium via LW-alphavbeta3 and CD44-CD44 interactions. Int J
Biochem Cell Biol. 2015; 65:40–51. doi: 10.1016/j.biocel.2015.05.013 PMID: 26007235
38. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of
sickle erythrocytes to the endothelium. Blood. 2001; 98(6):1955–62. PMID: 11535535
39. van Schravendijk MR, Handunnetti SM, Barnwell JW, Howard RJ. Normal human erythrocytes express
CD36, an adhesion molecule of monocytes, platelets, and endothelial cells. Blood. 1992; 80(8):2105–
14. PMID: 1382721
40. Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+
sickle reticulocytes to endothelial cells. Blood. 1992; 80(10):2634–42. PMID: 1384794
41. Shahani T, Lavend’homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M. Activation of
human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood.
2010; 115(23):4902–9. doi: 10.1182/blood-2009-07-232546 PMID: 20351306
42. Tokarev AA, Butylin AA, Ataullakhanov FI. Platelet adhesion from shear blood flow is controlled by
near-wall rebounding collisions with erythrocytes. Biophys J. 2011; 100(4):799–808. doi: 10.1016/j.bpj.
2010.12.3740 PMID: 21320422
43. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles cir-
culate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001; 85
(4):639–46. PMID: 11341498
44. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008; 451(7181):914–8. doi: 10.
1038/nature06797 PMID: 18288180
45. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012; 122
(7):2331–6. doi: 10.1172/JCI60229 PMID: 22751108
46. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, et al. von Willebrand factor-
mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011; 117
(4):1400–7. doi: 10.1182/blood-2010-05-287623 PMID: 20959603
Erythrocytes and von Willebrand factor
PLOS ONE | DOI:10.1371/journal.pone.0173077 March 1, 2017 19 / 19
